SCN5A and diabetic neuropathy: In 2016, Pfizer discontinued the development of PF 05089771 following insufficient efficacy in a Phase 2 trial against diabetic neuropathy.[37] This therapeutic formed part of a series of molecules[59] developed to target the VSD4 and provided the first series of Nav1.7 inhibitors with high selectivity over Nav1.5.